UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 736
- Registration Number
- NCT01255761
- Locations
- 🇺🇸
137, Birmingham, Alabama, United States
🇺🇸166, Huntsville, Alabama, United States
🇺🇸165, Peoria, Arizona, United States
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 221
- Registration Number
- NCT01242488
- Locations
- 🇺🇸
166, Mesa, Arizona, United States
🇺🇸154, Paradise Valley, Arizona, United States
🇺🇸118, Scottsdale, Arizona, United States
Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 192
- Registration Number
- NCT01236001
Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT01235403
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 41
- Registration Number
- NCT01235598
- Locations
- 🇩🇰
003, Frederiksberg, Denmark
🇩🇰002, Hellerup, Denmark
🇩🇰001, Hvidovre, Denmark
Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution
Completed
- Conditions
- Epilepsy
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 101
- Registration Number
- NCT01210690
- Locations
- 🇫🇷
012, Amiens, France
🇫🇷010, Bron, France
🇫🇷011, Paris, France
Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT01190410
- Locations
- 🇺🇸
114, Orange, California, United States
🇺🇸111, Aurora, Colorado, United States
🇺🇸103, Atlanta, Georgia, United States
Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 687
- Registration Number
- NCT01113710
Named Patient Program With Rotigotine Transdermal System
Completed
- Conditions
- Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 520
- Registration Number
- NCT01095484
- Locations
- 🇺🇸
088, Birmingham, Alabama, United States
🇺🇸082, Cullman, Alabama, United States
🇺🇸085, Fairhope, Alabama, United States
National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 12500
- Registration Number
- NCT01095393